HRS2398 / Jiangsu Hengrui Pharma - LARVOL DELTA

A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | N=122 ➔ 28 | Trial primary completion date: May 2023 ➔ Feb 2024

Enrollment change • Metastases • Trial completion • Trial primary completion date • Oncology • Solid Tumor

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=88 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=88 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor

A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1; N=116; Recruiting; Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastrointestinal Cancer • Oncology